Chemomab shares surge 29.66% after-hours after CEO to present at Oppenheimer Healthcare Conference.

Chemomab Therapeutics (Nasdaq: CMMB) surged 29.66% in after-hours trading following the announcement that CEO Dr. Adi Mor and senior management will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company highlighted its clinical-stage drug nebokitug, a first-in-class monoclonal antibody with FDA and EMA Orphan Drug designations and Fast Track status for treating primary sclerosing cholangitis. The presentation, webcast live and accessible for 90 days, along with one-on-one investor meetings, underscores Chemomab’s progress in fibro-inflammatory disease therapies and regulatory alignment for Phase 3 trials, likely driving investor optimism.